Related Experiment Video
Updated: Apr 30, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Treatment of small cell lung cancer
Alessandro Morabito1, Guido Carillio2, Gennaro Daniele3
1Medical Oncology Unit, Thoraco-Pulmonary Department, Istituto Nazionale Tumori, "Fondazione G. Pascale" - IRCCS, Napoli, Italy.
Abstract:
Treatment of small cell lung cancer (SCLC) remains a significant challenge for the oncologists. Attempts to improve the results of first-line treatment have all failed so far and no real progress has been made in last years, emphasizing the need for novel strategies of treatment and the development of validated biomarkers. Patients with limited disease and good performance status should be considered for concomitant chemoradiotherapy, followed by prophylactic cranial irradiation. Patients with extensive disease should be treated with a platinum-based chemotherapy (cisplatin or carboplatin); chest radiotherapy can be considered in patients achieving extra-thoracic complete response and prophylactic cranial irradiation is recommended for patients responsive to initial chemotherapy. A large number of molecular-targeted drugs and immunomodulators are currently in clinical development: however, only a better understanding of molecular biology of SCLC and the identification of molecular markers predictive of response to targeted agents will lead to advances in the treatment of SCLC.
Insights
Small cell lung cancer (SCLC) treatment is challenging, with limited progress. Novel strategies and biomarkers are crucial for advancing SCLC patient care and developing effective therapies.
Area of Science:
- Oncology
- Thoracic Oncology
- Cancer Research
Background:
- Small cell lung cancer (SCLC) treatment presents significant challenges for oncologists.
- Recent advancements in first-line treatment strategies for SCLC have been minimal.
- There is a critical need for novel therapeutic approaches and validated biomarkers in SCLC management.
Purpose of the Study:
- To review current treatment strategies for small cell lung cancer.
- To highlight the unmet needs in SCLC management.
- To discuss the potential of emerging molecular-targeted drugs and immunomodulators.
Main Methods:
- Review of current clinical guidelines and treatment protocols for SCLC.
- Analysis of recent clinical trial data for novel SCLC therapies.
- Discussion of the role of molecular biology and biomarkers in SCLC treatment.
Main Results:
- Concomitant chemoradiotherapy followed by prophylactic cranial irradiation is recommended for limited-stage SCLC with good performance status.
- Platinum-based chemotherapy is the standard for extensive-stage SCLC, with potential roles for chest radiotherapy and prophylactic cranial irradiation.
- Numerous molecular-targeted drugs and immunomodulators are in clinical development for SCLC.
Conclusions:
- Improved understanding of SCLC molecular biology and identification of predictive biomarkers are essential for therapeutic advances.
- Personalized treatment strategies based on molecular profiles hold promise for future SCLC management.
- Continued research into novel agents and combination therapies is necessary to overcome treatment resistance in SCLC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...